SNTI•benzinga•
Senti Biosciences Announces Release Of Its New Animated Video For Its Lead Asset In Development Senti-202 Cell Therapy Product Candidate Designed To Selectively Target And Eliminate CD33 And/Or FLT3-Expressing Hematologic Malignancies
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 8, 2025 by benzinga